Research & Development - Taj Pharma (Oncology)
Taj Pharmaceuticals has invested extensively in its Research & Development program to create different R&D facilities.
Taj Oncology aims to afford efficient cancer therapies through the discovery and development of innovative therapeutics that target the specific molecular pathways associated with cancer. Our capabilities lie in developing innovative, secure, and environment-friendly and price effective overall technologies to deliver high worth Oncology.
The R&D potential at Taj Oncology focuses on core scientific innovation, supervision of the various levels of drug development right from the pre clinical studies, managing clinical trials etc. It also looks into the development and validation of methods for innovative product development, product consistency monitoring and supporting manufacturing processes all the way up to commercialization.
Unique company - Absolute capability.
Taj is unique pharmaceutical company in manufacturing all types of oncology products with affordability, innovative in developing cancer medicines.
- We are in developing maximum number of different oncology products.
- The high quality of Bio-similars.(USP/BP)
- Products are Affordable and 70% less costly than the other Branded medicines in the market.
- Taj constantly involves in the development of the new products other than Patents.
Taj Oncology Research & Development
Drug Discovery
At Taj Oncology, Research & Development work seamlessly in an effort to bring new and better medicines to market in the shortest possible time.
This effort involves phases: an exploratory phase, during which a candidate compound is discovered and a proof of concept (PoC) is established through studies in patients; and a confirmatory phase, during which the drug enters full development when studies in large numbers of patients are conducted.
Research Approach
Rational drug design is a focused strategy for drug development that is grounded on a solid foundation in the basic sciences, driven by the rigor of laboratory research and proven clinically.
Read MoreClinical Trials
Open partnerships within the oncology care community enable us to conduct high-quality clinical trials with competitive timelines and aid in the discovery of new uses of our medicines to benefit patients. Taj oncology is currently conducting clinical trials in a number of disease areas.
Read MoreWHO-GMP-Certification.
WHO-GMP is the minimum certification that we follow in all our pharmaceutical units.
Our Research & Development
Research & development of Taj has been the organization of achievement and continues to be the major part of innovative, novel medicines for the treatment of diseases with the therapeutic need. Additionally, in our standard pursue for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners.
Who Are We
Taj Oncology is committed to the determine, explore and develop innovative treatment to improve the position of the cancer patients worldwide. This independent business unit within taj was established to enhance innovation while drawing on the capability and resources of the world's largest research-based pharmaceutical company.
Our pipeline of Taj Pharma explores that specific treatment approaches for various tumours, including such common types of cancer like prostate, lung and breast cancer, kidney, liver and thyroid cancer and many more.
How We Work
Taj Research & Development work together fluently in an effort to bring latest and improved medicines into market in the shortest period time.
Taj has broadest portfolios of oncology generic products with focus on market opportunities. The innovative product portfolio is a declaration to the Company’s capability in Research and Development. Our aim is to connect fundamental research to facilitate the transfer of modern scientific discoveries to the clinical care of patients. In this way we will hasten the provision of superior, more efficient and targeted treatments.
The R&D prospective at Taj Oncology focuses on core scientific innovation, supervision of the various levels of drug development from the pre-clinical studies, administration of the clinical trials etc. It looks in the development and justification of methods for innovative product development, product stability monitoring and supporting manufacturing process.
Taj already has developed more than +200 oncology products. People have to wait for Patents to explore.
Taj Pharma Group
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.
Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.
While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today." We have already progressed on such efforts by our current presence in more than 40 countries.
